Diwakar Davar

Diwakar Davar practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Diwakar Davar's NPI, 1295965523, was assigned on July 21, 2009. Diwakar Davar holds Pennsylvania license MD448208.

Diwakar Davar's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Diwakar Davar's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Diwakar Davar is also affiliated with UPMC Presbyterian. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Diwakar Davar to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Diwakar Davar practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Diwakar Davar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Diwakar Davar is licensed in Pennsylvania.

CMS data shows 665 Medicare services from Diwakar Davar across 7 procedure codes in 2024, for 299 Medicare patients. Medicare paid $65,994 for them.

CMS counts 299 Medicare patients who saw Diwakar Davar in 2024. The largest group is 65 to 74, with 136 patients. 67% of them have high blood pressure, and 66% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Diwakar Davar's median patient age at 75, with 40% women.

In 2024, Diwakar Davar wrote 249 Medicare Part D claims for 86 patients. 95% of them were for generic drugs. CMS names the drug for 143 of them, across 4 drugs with 11 or more claims each, at $2,809 in total drug cost. In 2023, CMS named 129 claims across 5 drugs.

Diwakar Davar accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 77 papers to Diwakar Davar, published from 2011 to 2025. 2024 was the busiest year, with 11. The most frequent topics are Melanoma, Immunotherapy and Immune Checkpoint Inhibitors. Diwakar Davar has published most often in J Immunother Cancer. Diwakar Davar's most frequent co-authors are Jason J. Luke, MD, Ahmad Tarhini, MD and Dylan Douglas Fortman, MD.

Dmand AI links Diwakar Davar to 12 clinical trials, 4 of them phase 2 studies. 10 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Merkel Cell. National Cancer Institute (NCI) sponsors the most, 7. Open Payments lists research payments to Diwakar Davar that name 6 trials.

CMS Open Payments shows 186 general payments to Diwakar Davar from 28 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 69% of the total. TriSalus Life Sciences, Inc. paid the most, $201,816. It also lists 13 research payments totaling $143,683 from 2018 to 2025, naming 6 clinical trials.